MT-5625 / Mitsubishi Tanabe - LARVOL DELTA

Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted time-series analysis. (PubMed, Vaccine) - "Rotavirus vaccination has resulted in a significant decline in all-cause and rotavirus-specific AGE, and thus, provides strong evidence for public health policy makers in Kenya to support the sustained use of the rotavirus vaccine in routine immunization. However, the shift in strain dominance and age distribution of rotavirus AGE in the post-vaccine era underscores the need for continued surveillance to assess any possible vaccine-induced selective pressure that could diminish the vaccine effectiveness over time."

Journal • Gastroenterology • Gastrointestinal Disorder • Rotavirus Infections

Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. (PubMed, Vaccine) - P1 | "The Ro-VLP vaccine was well tolerated and induced a homotypic immune response in infants, suggesting that this technology platform is a favorable approach for a parenteral non-replicating rotavirus vaccine."

Clinical • Journal • Rotavirus Infections

Development and characterization of a plant-derived rotavirus-like particle vaccine. (PubMed, Vaccine) - "Plant-derived Ro-VLP composed of VP7, VP6 and VP2 structural proteins would be a plausible alternative to live-attenuated oral rotavirus vaccines currently distributed worldwide."

Journal • Rotavirus Infections

Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants (clinicaltrials.gov) - P1; N=110; Completed; Sponsor: Mitsubishi Tanabe Pharma Corporation; Active, not recruiting ➔ Completed

Clinical • Trial completion

Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants (clinicaltrials.gov) - P1; N=110; Active, not recruiting; Sponsor: Mitsubishi Tanabe Pharma Corporation; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed